



Clinical-Bladder cancer

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer

David D'Andrea, M.D.^a, Peter C. Black, M.D.^b, Homayoun Zargar, M.D.^{b,c}, Kamran Zargar-Shoshtari, M.D.^{d,e}, Sonja Zehetmayer, Ph.D.^f, Adrian S. Fairey, M.D.^g, Laura S. Mertens, M.D.^h, Colin P. Dinney, M.D.ⁱ, Maria C. Mir, M.D.^{j,k}, Laura-Maria Krabbe, M.D.^{l,m}, Michael S. Cookson, M.D.ⁿ, Niels-Erik Jacobsen, M.D.^g, Jeffrey S. Montgomery, M.D.^o, Nikhil Vasdev, M.D.^{p,q}, Evan Y. Yu, M.D.^r, Evangelos Xylinas, M.D.^s, Nicholas J. Campain, M.D.^t, Wassim Kassouf, M.D.^u, Marc A. Dall'Era, M.D.^v, Jo-An Seah, M.D.^w, Cesar E. Ercole, M.D.^j, Simon Horenblas, M.D.^h, Srikala S. Sridhar, M.D.^w, John S. McGrath, M.D.^t, Jonathan Aning, M.D.^{t,x}, Jonathan L. Wright, M.D.^y, Andrew C. Thorpe, M.D.^q, Todd M. Morgan, M.D.^o, Jeffrey M. Holzbeierlein, M.D.^z, Trinity J. Bivalacqua, M.D.^{aa}, Scott North, M.D.^{bb,cc}, Daniel A. Barocas, M.D.^{dd}, Yair Lotan, M.D.^l, Petros Grivas, M.D.^{r,ee}, Andrew J. Stephenson, M.D.^j, Jay B. Shah, M.D.^{i,ff}, Bas W. van Rhijn, M.D.^h, Siamak Daneshmand, M.D.^{gg}, Philippe E. Spiess, M.D.^d, Shahrokh F. Shariat, M.D.^{a,l,hh,ii,jj,*}

^a Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

^b Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

^c Western Health, Melbourne, Australia

^d Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

^e University of Auckland, Auckland, New Zealand

^f Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria

^g University of Alberta, Edmonton, AB, Canada

^h Department of Urology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

ⁱ Department of Urology, MD Anderson Cancer Center, Houston, TX

^j Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH

^k Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain

^l Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX

^m Department of Urology, University of Münster, Münster, Germany

ⁿ Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK

^o Department of Urology, University of Michigan Health System, Ann Arbor, MI

^p Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK

^q Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK

^r Department of Medicine, Division of Oncology, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA

^s Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France

^t Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK

^u Department of Surgery (Division of Urology), McGill University Health Center, Montreal, Canada

^v Department of Urology, University of California at Davis, Davis Medical Center, Sacramento, CA

^w Princess Margaret Hospital, Toronto, ON, Canada

^x Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK

^y Department of Urology, University of Washington, Seattle, WA

^z Department of Urology, University of Kansas Medical Center, Kansas City, KS

^{aa} Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Baltimore, MD

^{bb} Cross Cancer Institute, Edmonton, AB, Canada

*Corresponding author at: Department of Urology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

Tel.: +43 40400 26 150.

E-mail address: sfshariat@gmail.com (S.F. Shariat).

^{cc} Department of Oncology, University of Alberta, Edmonton, AB, Canada^{dd} Department of Urology, Vanderbilt University Medical Center, Nashville, TN^{ee} Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH^{ff} Department of Urology, Stanford University School of Medicine, Stanford, CA^{gg} USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA^{hh} Departments of Urology, Weill Cornell Medical College, New York, New Yorkⁱⁱ Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic^{jj} Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Received 10 November 2019; received in revised form 24 December 2019; accepted 21 January 2020

Abstract

Objective: To assess the effect of patient's sex on response to neoadjuvant chemotherapy (NAC) in patients with clinically nonmetastatic muscle-invasive bladder cancer (MIBC).

Methods: Complete pathologic response, defined as ypT0N0 at radical cystectomy, and downstaging were evaluated using sex-adjusted univariable and multivariable logistic regression modeling. We used interaction terms to account for age of menopause and smoking status. The association of sex with overall survival and cancer-specific survival was evaluated using Cox regression analyses.

Results: A total of 1,031 patients were included in the analysis, 227 (22%) of whom were female. Female patients had a higher rate of extravesical disease extension ($P = 0.01$). After the administration of NAC, ypT stage was equally distributed between sexes ($P = 0.39$). On multivariable logistic regression analyses, there was no difference between the sexes or age of menopause with regards to ypT0N0 rates or downstaging (all $P > 0.5$). On Cox regression analyses, sex was associated with neither overall survival (hazard ratio 1.04, 95% confidence interval 0.75–1.45, $P = 0.81$) nor cancer-specific survival (hazard ratio 1.06, 95% confidence interval 0.71–1.58, $P = 0.77$).

Conclusion: Our study generates the hypothesis that NAC equalizes the preoperative disparity in pathologic stage between males and females suggesting a possible differential response between sexes. This might be the explanation underlying the comparable survival outcomes between sexes despite females presenting with more advanced tumor stage. © 2020 Elsevier Inc. All rights reserved.

Keywords: Sex; Bladder cancer; Neoadjuvant chemotherapy; Response

1. Introduction

Patient sex (female vs. male) has a differential effect on bladder cancer (BCa) presentation and survival [1,2]. While BCa incidence is 3 to 4 times higher in males compared to females, the latter are more likely to be diagnosed with advanced disease and to suffer from worse survival outcomes despite standard treatment [3–5]. Neoadjuvant chemotherapy (NAC) is part of the standard of care therapeutic modalities delivered in patients with clinically nonmetastatic muscle-invasive BCa (MIBC) [6,7]. However, females are less likely to receive NAC which is partially explained by differences in health care factors like time to diagnosis and treatment modality [8–11].

To the best of our knowledge, there is no data on a potentially differential response to NAC according to sex in patients treated with radical cystectomy (RC). To fill this gap, we compared pathologic response rates and survival outcomes between sexes adjusting for the effects of smoking and age suggestive of menopause in a large multicenter dataset of patients treated with NAC followed by RC for BCa.

2. Material and methods

2.1. Study population

We performed a retrospective analysis of our multi-institutional database comprising 1,474 patients treated

with NAC followed by RC for BCa from 2000 to 2013 [7].

Patients with clinically metastatic disease (N+ and/or M+) were excluded, leaving 1,031 patients for final analysis. A total of 313 patients were lost to follow-up, leaving 718 patients for survival analyses. Clinical stage prior to the administration of chemotherapy was assigned by the treating physician based on transurethral resection of the bladder, bimanual exam, and/or cross-sectional imaging.

2.2. Chemotherapy

NAC regimens consisted of cisplatin-based combination chemotherapy, or other. Chemotherapy regimen and number of cycles were administered at clinician discretion in accordance with institutional standards and guidelines at that time.

2.3. Radical cystectomy

Patients were treated with RC and lymphadenectomy. All procedures were performed by an open technique. The decision for the type of urinary diversions was based on patient and disease characteristics, patient's and surgeon's preferences as well as patient's performance status. All surgical specimens were processed according to standard pathologic procedures and staged according to the 1998 TNM classification. All tumors were high grade.

2.4. Outcome measurement

Response to NAC was assessed by yTNM stage at RC. Complete pathologic response was defined as ypT0N0. Downstaging was defined as any stage migration from non-organ confined disease to ypT2-N0, nonmuscle-invasive bladder cancer (ypNMIBC)-N0 or ypT0-N0 or from cT2 to ypNMIBC-N0 or ypT0-N0. Overall survival (OS) and cancer-specific survival (CSS) were calculated from the day of RC until death of any cause for OS and death due to BCa for CSS, respectively. Patients were censored at the time of last follow up. Cause of death was recorded through patients charts and/or death certificates [12].

2.5. Molecular correlates of response to chemotherapy

Since both RNA expression subtypes and mutations in specific DNA damage response (DDR) genes have been shown to correlate with response to NAC in patients with MIBC, we investigated the prevalence of subtypes and DDR gene alterations according to sex using data from 395 chemo-naïve patients with MIBC from The Cancer Genome Atlas (TCGA) Program [13]. The TCGA subtypes (luminal papillary, luminal infiltrated, luminal, basal squamous, and neuronal) were used. We selected ERCC2 [14] as well as RB1, ATM, and FANCC [15] as key DDR genes based on prior reports, but also added ATR, BRCA1, BRCA2, ERCC5, RAD51C, and REQLC4 based on the list of DDR genes selected as functionally important in the Alliance A031701 trial investigating bladder preservation after NAC (NCT03609216) [16].

2.6. Statistical analysis

We performed a stepwise approach to the statistical analyses. First, we performed multiple imputation by using chained equations to handle missing data that were assumed to be missing at random. Fifteen imputed data sets were generated using predictive mean matching for numeric variables, logistic regression for binary variables, and Bayesian polytomous regression for factor variables. Second, we compared the distribution of patients' clinicopathologic features according to sex. Third, we evaluated the association of sex with pathologic response using univariable and multivariable logistic regression modeling. Due to the even distribution of the data between groups, adjustments using propensity score were not performed. Fourth, as preplanned analysis, we introduced interaction terms in the logistic models to evaluate the synergistic effect of sex and smoking status or menopausal status. As the age of menopause was not available, we arbitrarily assigned the age of 50 as cut-off for menopause. Fifth, we investigated the association of sex with OS and CSS using Cox regression analyses and plotted survival curves using the Kaplan-Meier method. Sixth, we tested the validity of the Cox model assumption using Schoenfeld residuals. Due to the

exploratory character of the study, statistical significance was considered at $P < 0.05$, but not in a confirmatory manner. Therefore, no adjustment for multiplicity was performed. All tests were performed with R (R Foundation for Statistical Computing, v3.5.1).

3. Results

Clinicopathologic features of the population are shown in Table 1. Overall, 804 (78%) patients were of male sex and 227 (22%) were of female sex. Females had more advanced clinical stage at presentation than their male counterparts (nonorgan confined disease 36.6% vs. 32.6%).

We observed an equal distribution of ypT stage between sexes after NAC (Fig. 1). On univariable logistic regression analyses, we could not identify an association of sex with downstaging or complete pathologic response to NAC (all $P > 0.5$). Multivariable analyses which adjusted for the

Table 1

Clinicopathologic features of 1,031 patients treated with neoadjuvant chemotherapy and radical cystectomy for clinically nonmetastatic muscle-invasive bladder cancer, stratified by sex

	Male	female	<i>P</i>
<i>n</i> (%)	804 (78)	227 (22)	
Age, median (IQR)	63 (57–71)	65 (58–72)	0.11
Smoking, <i>n</i> (%)			0.02
Never	292 (36.3)	100 (44.1)	
Former	451 (56.1)	119 (52.4)	
Current	61 (7.6)	8 (3.5)	
Histology, <i>n</i> (%)			0.98
Urothelial	705 (87.7)	201 (88.5)	
Mixed histological variant*	99 (12.3)	26 (11.5)	
Chemotherapy regimen, <i>n</i> (%)			0.73
Cisplatin-based	670 (83.3)	192 (84.6)	
Other	134 (16.7)	35 (15.4)	
Chemotherapy cycles, <i>n</i> (%)			0.13
1–2	76 (9.5)	32 (14.1)	
3–4	679 (84.5)	182 (80.2)	
5–8	49 (6.1)	13 (5.7)	
cT, <i>n</i> (%)			0.01
cT2	510 (63.4)	131 (57.7)	
cT3	195 (24.3)	77 (33.9)	
cT4	99 (12.3)	19 (8.4)	
ypT, <i>n</i> (%)			0.39
ypT0	190 (23.6)	48 (21.1)	
ypNMIBC	164 (20.4)	46 (20.3)	
ypT2	160 (19.9)	38 (16.7)	
ypT3/T4	290 (36.1)	95 (41.9)	
ypN, <i>n</i> (%)			0.76
ypN0	642 (79.9)	174 (76.7)	
ypN1	64 (8.0)	20 (8.8)	
ypN2	85 (10.6)	29 (12.8)	
ypN3	13 (1.6)	4 (1.8)	
Nodes removed, median (IQR)	18 (11–27)	16 (11–25)	0.11
Positive STSM, <i>n</i> (%)	65 (8.1)	16 (7.0)	0.71

IQR = interquartile range; NMIBC = nonmuscle-invasive bladder cancer; STSM = soft tissue surgical margin.

* Mixed histological variant includes adenocarcinoma, neuroendocrine carcinoma, and squamous carcinoma.




Fig. 1. Alluvial diagram for the changes of cT stage to ypT stage in 1,031 patients treated with neoadjuvant chemotherapy (NAC) and radical cystectomy for clinically nonmetastatic muscle-invasive bladder cancer, stratified by sex.

effects of clinical stage, administered NAC regimen, number of cycles, and smoking status, failed to identify a significant difference between females and males in downstaging or complete pathologic response to NAC when comparing the means between the 2 populations in the overall model (all $P > 0.5$; Table 2).

Overall, 207 (91%) female patients were 50 years or older. Of these, 91 (44%) were never smokers, 109 (53%) former smokers, and 7 (3%) current smokers. On univariable and multivariable logistic regression analyses, we could not identify an association of menopausal status with complete response to NAC or downstaging (all $P > 0.5$; Table 3).

Table 2

Logistic regression analyses for the association of sex and smoking with downstaging and ypT0N0 status in 1,031 patients treated with neoadjuvant chemotherapy and radical cystectomy for clinically nonmetastatic muscle-invasive bladder cancer

Univariable analysis	Downstaging OR (95%CI)	P	ypT0N0 OR (95%CI)	P
Female vs. male sex	0.92 (0.68–1.24)	0.59	0.87 (0.60–1.23)	0.44
Smoker				
Never	Ref		Ref	
Former	1.06 (0.82–1.38)	0.63	0.90 (0.66–1.22)	0.49
Current	0.74 (0.44–1.24)	0.25	0.73 (0.37–1.37)	0.35
Multivariable analysis	Downstaging OR (95%CI)	P	ypT0N0 OR (95%CI)	P
Female vs. male sex	0.82 (0.51–1.31)	0.40	1.18 (0.69–1.98)	0.54
Smoking status				
Never	Ref		Ref	
Former	1.01 (0.75–1.36)	0.96	1.01 (0.72–1.45)	0.93
Current	0.77 (0.43–1.36)	0.37	0.75 (0.36–1.46)	0.41
Clinical T stage				
cT2	Ref		Ref	
cT3	1.31 (0.98–1.75)	0.07	0.73 (0.51–1.03)	0.08
cT4	1.29 (0.86–1.93)	0.21	0.89 (0.54–1.41)	0.63
Cisplatin-based chemotherapy	2.09 (1.48–2.99)	<0.01	1.46 (0.96–2.28)	0.08
Chemotherapy cycles				
1–2	Ref		Ref	
3–4	1.28 (0.85–1.94)	0.23	1.18 (0.73–1.98)	0.52
5–8	0.84 (0.43–1.60)	0.59	0.84 (0.36–1.87)	0.68
Sex female: smoke former	1.16 (0.62–2.15)	0.64	0.57 (0.27–1.21)	0.15
Sex female: smoke current	1.41 (0.29–6.97)	0.66	0.50 (0.02–3.55)	0.55
	<i>F</i> -statistics 2.79, $P = 0.002$		<i>F</i> -statistics 1.12, $P = 0.34$	

CI = confidence interval; OR = odds ratio.

Table 3

Logistic regression analyses for the association of menopausal status and smoking with downstaging and ypT0N0 status in 227 female patients treated with neoadjuvant chemotherapy and radical cystectomy for clinically nonmetastatic muscle-invasive bladder cancer

Univariable analysis	Downstaging OR (95%CI)	<i>P</i>	ypT0N0 OR (95%CI)	<i>P</i>
Age ≥50 years*		0.88	1.05 (0.36–3.80)	0.93
Smoker				
Never	Ref		Ref	
Former	1.19 (0.70–2.04)	0.51	0.57 (0.29–1.10)	0.09
Current	1.17 (0.26–5.21)	0.83	0.41 (0.02–2.44)	0.41
Multivariable analysis	Downstaging OR (95%CI)	<i>P</i>	ypT0N0 OR (95%CI)	<i>P</i>
Age ≥50 years*	0.50 (0.11–2.11)	0.35	1.25 (0.27–9.02)	0.79
Smoking status				
Never	Ref		Ref	
Former	0.37 (0.05–2.41)	0.30	0.88 (0.08–9.33)	0.91
Current	1.25e+06 (1.35e–72–NA)	0.99	1.60e–06 (NA–1.12e+72)	0.99
Clinical T stage				
cT2	Ref		Ref	
cT3	1.20 (0.67–2.14)	0.54	0.85 (0.41–1.72)	0.67
cT4	0.55 (0.18–1.51)	0.26	0.34 (0.05–1.33)	0.17
Cisplatin-based chemotherapy	2.21 (1.02–5.08)	0.05	0.96 (0.40–2.51)	0.93
Chemotherapy cycles				
1–2	Ref		Ref	
3–4	1.41 (0.65–3.19)	0.39	0.71 (0.29–1.83)	0.45
4–8	1.61 (0.41–6.35)	0.49	1.76 (0.38–7.73)	0.46
Sex female: smoke former	3.33 (0.47–25.6)	0.23	0.58 (0.05–6.79)	0.65
Sex female: smoke current	7.07e–07 (NA–4.28e+71)	0.99	3.37e+05 (7.43e–61–NA)	0.99
	<i>F</i> -statistics 0.89, <i>P</i> = 0.54		<i>F</i> -statistics 0.71, <i>P</i> = 0.72	

CI = confidence interval; OR = odds ratio.

* As the age of menopause was not available, we arbitrarily assigned the age of 50 as cut-off for menopause.

Within a median follow-up of 17 months (interquartile range 7–37), 297 (41%) patients died, and 206 (29%) died of their BCa. On Cox regression analyses, female sex was neither associated with OS (hazard ratio [HR] 0.98, 95% confidence interval [CI] 0.69–1.38, *P* = 0.89) nor CSS (HR 1.03, 95%CI 0.69–1.55, *P* = 0.88; Fig. 2). The validity of the proportional hazard assumption was supported by a nonsignificant relationship between residuals and time (*P* = 0.99).

In a final step, we extracted TCGA data [13] and analyzed the prevalence of 10 DDR genes (ATM, ATR, BRCA1,

BRCA2, ERCC2, ERCC5, FANCC, RAD51C, RB1, and REQLC4) between males and females. We found that females have fewer DDR gene mutations overall compared to males (28.3% vs. 44.6%, *P* < 0.001). However, there was no difference in the rate of single DDR gene mutations between sexes (Supplementary Fig. S1). With respect to RNA-based subtypes, basal squamous was more frequent in females (43.4% vs. 37.7%) and luminal papillary in males (37.7% vs. 28.3%). However, these differences were not statistically significant (all *P* ≥ 0.05, Supplementary Fig. S2).




Fig. 2. Kaplan-Meier curves for the association of sex with overall (A) and cancer-specific survival (B) in 718 patients treated with neoadjuvant chemotherapy and radical cystectomy for clinically nonmetastatic bladder cancer.

4. Discussion

In a retrospective analysis of a large multicenter cohort of patients treated with NAC followed by RC for nonmetastatic BCa there was a small but statistically significant difference in clinical T stage at diagnosis. This difference between sexes could no longer be observed after NAC. However, on logistic regression analysis, we could not observe an association of sex with pathologic complete response to NAC.

Although the incidence of BCa in females is lower than in males, female patients often present with more advanced disease and suffer from worse prognosis [1,2,17]. In this context, genetic, environmental, hormonal, and health care differences are known to play a role in response to standard therapies and oncologic outcomes [8,18]. However, a definitive and satisfactory explanation for these sex-based differences is still missing. We tried to shed light on this, by investigating the synergistic effect of smoking and cut-off age of 50, as surrogate for menopause [19], on response to NAC. We found no association of either age or smoking status with response to NAC. This is known to be different compared to exposure to checkpoint inhibitors in metastatic BCa [20]. However, less than 10% of the women in this cohort were under age 50 and a difference may be difficult to identify.

Smoking is a well-known risk factor for BCa [21,22]. Population-based studies have shown that among smokers, females have a higher risk of developing BCa compared to males (HR 2.75 for female vs. 2.32 for male) [23]. However, the synergistic effect of smoking and sex is not consistent in the literature [24,25]. In preclinical studies, smoking has been linked to chemoresistance in human BCa cell line [26]. However, the clinical literature presents controversial results regarding smoking status as predictor of chemoresistance, even when stratified by sex [27–30].

In our study, we expanded upon previous findings by investigating the synergistic effect of smoking and sex on the response to NAC in a large population with clinically nonmetastatic MIBC. We could not identify a statistically significant association of smoking status with downstaging or complete response to NAC. This effect can partially be explained by the low patient number in relation to the difference between groups. Indeed, if we look at the reported effect in population-based studies [23,31], a larger cohort would, probably, be needed to show a statistically significant difference between males and females.

Preclinical studies have shown that the modulation of circulating estrogen levels through the menopausal status leads to structural changes in the murine bladder [32,33]. In clinical studies, sex-based differences in hormonal status have been linked to the development and progression of BCa [33,34].

We investigated the association of age, using the cut-off of 50 years as surrogate for menopause, with pathological response to NAC. We, indeed, found no significant association with any of the outcomes. These findings are in line with the current literature. For example, in a case-control

study with a meta-analysis, Dietrich et al. found that postmenopausal females were at higher risk for developing a BCa, but this association was not statistically significant (odds ratio [OR] 1.30, 95%CI 0.45–3.77). Those authors also reported that the OR increased with the age of menopause of <45 years (OR 1.33, 95%CI 0.72–2.47) [35]; but again, this association was not significant. Differences in tumor biology, change in sex steroid receptor after menopause, and the potential association of BCa with sex steroid hormones may explain this phenomenon [36].

Somatic genetic alterations in DDR genes and molecular subtypes have been linked to clinical response to cisplatin-based NAC [14,15,37]. Choi et al. have also reported that tumors of the basal subtype, which appear to benefit most from NAC, are enriched in women [37]. In order to evaluate whether differences in these 2 molecular parameters could explain the differential response to NAC in female, we analyzed the TCGA data. We found that males had overall more DDR gene mutations than females, which would weigh against a better response to NAC in women. On the other hand, we could not identify a statistically significant difference in the rate of single DDR gene mutations or prevalence of mRNA cluster between sexes. Altogether, these molecular findings do not clearly explain the modest differential response rate to NAC between males and females.

Complete pathologic response after NAC has been correlated with improved OS and RFS [38,39]. We investigated the association of sex with survival and found no statistical difference in OS and CSS. In contrast to our findings, in a retrospective analysis of 4,216 patients treated with RC without NAC, Messer et al. found a significant association of female sex with recurrence ($P=0.039$) and CSS ($P=0.001$) [40]. The explanation for these disparities is likely multifactorial [1,2,41]. In our study, all patients were treated with NAC, which might have potentially abrogated clinical differences in survival. Indeed, we observed no difference in pathologic T or N stage between sexes after NAC. This is an important finding which generates the hypothesis that sex-based differences and pathologic features in BCa may be equalized through the administration of NAC, leading to comparable oncologic outcomes.

We acknowledge the limitations of our study, which are mainly inherent to its retrospective design and the short follow-up. Staging and the administration of NAC were not standardized. Moreover, given anatomical differences between sexes, females may have been diagnosed with more advanced clinical stage compared to males. We could not account for the quality of surgical techniques. Indeed, the extent of resection and lymphadenectomy may have possibly influenced outcomes. Previous reports could not show a significant difference between sexes in patients treated with incomplete or complete TURB before NAC. For example, James et al. investigated the association of maximal TURB with complete pathologic response to NAC. Among 81 patients who received NAC, those treated with maximal TURB were more likely to achieve complete

pathologic response (OR 3.17, 95%CI 1.02–9.83). Stratified by sex, females were more likely to achieve complete pathologic response. However, this association was statistically not significant [42].

In addition, the anatomic difference in bladder wall thickness between males and females could also have influenced outcomes by allowing a more radical resection in females.

In this context, it can be argued that nodal staging could be a more accurate end-point to assess response to NAC, as lymph nodes are not affected by any surgical intervention prior to NAC administration. In a previous retrospective analysis of 304 patients with clinically N+ treated with induction chemotherapy followed by RC, we found that a complete pathological response can be achieved in 14.5% of the patients. However, the authors could not detect any differences in response to chemotherapy between sexes [43]. Finally, this study did not evaluate the association of sex with NAC-related toxicity, morbidity, and mortality.

Despite these limitations, our study provides clinically relevant information and generates the hypothesis that NAC could reduce the survival gap between males and females by equalizing sex-specific differences in clinical stage emphasizing the adoption of multimodal treatment modalities in the era of personalized medicine [44].

5. Conclusion

We found that, in patients planned for NAC and RC, females have worse clinicopathologic features compared to males at the time of diagnosis. After the administration of NAC this small difference between sexes disappeared. Our analyses generate the hypothesis of a differential response to NAC between sexes which could potentially equalize the clinical outcomes of patients with different prognosis. Further research should focus on sex-based differences in response the novel systemic agents such as immune-therapeutics and anti-fibroblast growth factor receptors therapy agent, as well as trimodal therapy [45].

Conflict of interest

Dr. D'Andrea has nothing to disclose.

Dr. Black reports personal fees from AbbVie, Asieris, AstraZeneca, Astellas, Bayer, Biosyent, BMS, H3-Biomedicine, Janssen, Merck, Roche, Sanofi, Urogen, Ferring, TerSera, Pfizer, GenomeDx Biosciences, iProgen, Genentech, Sitka, MDx Health outside the submitted work; in addition, Dr. Black shares a patent with GenomeDx.

Dr. Zargar has nothing to disclose.

Dr. Zargar-Shoshtari has nothing to disclose.

Dr. Zehetmayer has nothing to disclose.

Dr. Fairey has nothing to disclose.

Dr. Mertens has nothing to disclose.

Dr. Dinney has nothing to disclose.

Dr. Mir has nothing to disclose.

Dr. Krabbe has nothing to disclose.

Dr. Cookson reports personal fees from Myovant Sciences, Janssen, Astellas, Bayer, Ferring outside of the submitted work.

Dr. Jacobsen has nothing to disclose.

Dr. Montgomery has nothing to disclose.

Dr. Vasdev has nothing to disclose.

Dr. Yu reports personal fees from Amgen, personal fees from Astrazeneca, grants and personal fees from Bayer, personal fees from Clovis, grants and personal fees from Dendreon, personal fees from Janssen, grants and personal fees from Merck, personal fees from Pharmacyclics, grants and personal fees from Seattle Genetics, outside the submitted work.

Dr. Xylinas has nothing to disclose.

Dr. Campain has nothing to disclose.

Dr. Kassouf has nothing to disclose.

Dr. Dall'Era has nothing to disclose.

Dr. Seah has nothing to disclose.

Dr. Ercole has nothing to disclose.

Dr. Horenblas has nothing to disclose.

Dr. Sridhar has nothing to disclose.

Dr. McGrath has nothing to disclose.

Dr. Aning has nothing to disclose.

Dr. Wright has nothing to disclose.

Dr. Thorpe has nothing to disclose.

Dr. Morgan has nothing to disclose.

Dr. Holzbeierlein has nothing to disclose.

Dr. Bivalacqua has nothing to disclose.

Dr. North has nothing to disclose.

Dr. Barocas has nothing to disclose.

Dr. Lotan has nothing to disclose.

Dr. Grivas reports personal fees from AstraZeneca; Bayer; Biocept; Bristol-Myers Squibb; Clovis Oncology; Dendreon; Driver; EMD Serono; Exelixis; Foundation Medicine; Genentech; Genzyme; Heron Therapeutics; Janssen; Merck & Co.; Mirati Therapeutics; Pfizer; Seattle Genetics; QED Therapeutics; Grants from AstraZeneca, Bayer; Genentech/Roche; Merck & Co.; Mirati Therapeutics; Oncogenex; Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm, Bristol-Myers Squibb outside of the submitted work.

Dr. Stephenson has nothing to disclose.

Dr. Shah has nothing to disclose.

Dr. Rhijn has nothing to disclose.

Dr. Daneshmand has nothing to disclose.

Dr. Spiess has nothing to disclose.

Dr. Shariat reports personal fees from Astellas, AstraZeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi, Wolff, outside the submitted work; in addition he has following patents: Method to determine prognosis after therapy for prostate cancer; Granted 2002-09-06, Method to determine prognosis after therapy for bladder cancer; Granted 2003-06-19, Prognostic methods for patients with prostatic disease; Granted 2004-08-05, Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma; Granted 2010-07-20.

Acknowledgment

We would like to thank Kenichiro Ikeda for data extraction from The Cancer Genome Atlas Program.

Supplementary materials

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.uroclonc.2020.01.010>.

References

- [1] Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. *Eur Urol* 2016;69:300–10. <https://doi.org/10.1016/j.eururo.2015.08.037>.
- [2] Lucca I, Klatter T, Fajkovic H, de Martino M, Shariat SF. Gender differences in incidence and outcomes of urothelial and kidney cancer. *Nat Rev Urol* 2015;12:653. <https://doi.org/10.1038/nrurol.2015.257>.
- [3] Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. *World J Urol* 2011;29:457–63. <https://doi.org/10.1007/s00345-011-0709-9>.
- [4] Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. *Cancer Epidemiol* 2013;37:219–25. <https://doi.org/10.1016/j.canep.2013.02.002>.
- [5] Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. *BJU Int* 2010;105:300–8. <https://doi.org/10.1111/j.1464-410x.2009.09076.x>.
- [6] Witjes AJ, Lebet T, Comp erat EM, Cowan NC, Santis M, Bruins H, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. *Eur Urol* 2017;71:462–75. <https://doi.org/10.1016/j.eururo.2016.06.020>.
- [7] Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Eur Urol* 2015;67:241–9. <https://doi.org/10.1016/j.eururo.2014.09.007>.
- [8] Rose TL, Deal AM, Nielsen ME, Smith AB, Milowsky MI. Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer. *Cancer* 2016;122:2012–20. <https://doi.org/10.1002/ncr.30029>.
- [9] Konety DR, Joslyn SA. Factors influencing aggressive therapy for bladder cancer: an analysis of data from the SEER program. *J Urol* 2003;170:1765–71. <https://doi.org/10.1097/01.ju.0000091620.86778.2e>.
- [10] Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. *Cancer* 2009;115:68–74. <https://doi.org/10.1002/ncr.23986>.
- [11] Krimphove MJ, Szymaniak J, Marchese M, Tully KH, D'Andrea D, Mossanen M, et al. Sex-specific differences in the quality of treatment of muscle-invasive bladder cancer do not explain the overall survival discrepancy. *Eur Urol Focus* 2019. <https://doi.org/10.1016/j.euf.2019.06.001>.
- [12] Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, et al. Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. *Eur Urol* 2012;61:854–5. <https://doi.org/10.1016/j.eururo.2011.12.055>.
- [13] Robertson GA, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. *Cell* 2017;171:540–56. <https://doi.org/10.1016/j.cell.2017.09.007>:e25.
- [14] Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. *Cancer Discov* 2014;4:1140–53. <https://doi.org/10.1158/2159-8290.cd-14-0623>.
- [15] Plimack ER, Dunbrack RL, Brennan TA, Andrade MD, Zhou Y, Serbriiskii IG, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. *Eur Urol* 2015;68:959–67. <https://doi.org/10.1016/j.eururo.2015.07.009>.
- [16] Alliance A031701: a phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations, n.d.
- [17] Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Roupr t M, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. *Eur Urol* 2014;66:913–9. <https://doi.org/10.1016/j.eururo.2013.11.040>.
- [18] Noon A, Albertsen P, Thomas F, Rosario D, Catto J. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. *Br J Cancer* 2013;108:1534. <https://doi.org/10.1038/bjc.2013.106>.
- [19] Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. *Urol Oncol Semin Orig Invest* 2009;27:653–67. <https://doi.org/10.1016/j.uroclonc.2009.07.020>.
- [20] Conforti F, Pala L, Bagnardi V, Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. *Lancet Oncol* 2018;19:737–46. [https://doi.org/10.1016/s1470-2045\(18\)30261-4](https://doi.org/10.1016/s1470-2045(18)30261-4).
- [21] Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol* 2013;64:456–64. <https://doi.org/10.1016/j.eururo.2012.11.039>.
- [22] Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, Shariat SF. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. *Eur Urol* 2014;65:742–54. <https://doi.org/10.1016/j.eururo.2013.06.010>.
- [23] Jacob L, Freyn M, Kalder M, Dinas K, Kostev K. Impact of tobacco smoking on the risk of developing 25 different cancers in the UK: a retrospective study of 422,010 patients followed for up to 30 years. *Oncotarget* 2018;9:17420–9. <https://doi.org/10.18632/oncotarget.24724>.
- [24] Janisch F, Shariat SF, Scherhammer E, Rink M, Fajkovic H. The interaction of gender and smoking on bladder cancer risks. *Curr Opin Urol* 2019;1. <https://doi.org/10.1097/mou.0000000000000602>.
- [25] Krabbe L-M, Svatek RS, Shariat SF, Messing E, Lotan Y. Bladder cancer risk: use of the PLCO and NLST to identify a suitable screening cohort. *Urol Oncol Semin Orig Invest* 2015;33:65.e19–25. <https://doi.org/10.1016/j.uroclonc.2014.06.009>.
- [26] Chen R-J, Ho Y-S, Guo H-R, Wang Y-J. Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. *Toxicol Sci* 2010;115:118–30. <https://doi.org/10.1093/toxsci/kfq028>.
- [27] Kim PH, Kent M, Zhao P, Sfakianos JP, Bajorin DF, Bochner BH, et al. The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. *World J Urol* 2014;32:453–9. <https://doi.org/10.1007/s00345-013-1128-x>.
- [28] Boeri L, Soligo M, Frank I, Boorjian SA, Thompson RH, Tollefson M, et al. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. *BJU Int* 2019. <https://doi.org/10.1111/bju.14612>.
- [29] Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, et al. The effectiveness of off-protocol adjuvant chemotherapy for

- patients with urothelial carcinoma of the urinary bladder. *Clin Cancer Res* 2010;16:4461–7. <https://doi.org/10.1158/1078-0432.ccr-10-0457>.
- [30] Fantini D, Seiler R, Meeks JJ. Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients. *Urol Oncol Semin Orig Investig* 2018. <https://doi.org/10.1016/j.urolonc.2018.09.017>.
- [31] Abufaraj M, Shariat S, Moschini M, Markt S, Zhang H, Schernhammer E, et al. The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from nurses' health study and nurses' health study II. *Eur Urol Suppl* 2019;18:e235. [https://doi.org/10.1016/s1569-9056\(19\)30172-1](https://doi.org/10.1016/s1569-9056(19)30172-1).
- [32] Aikawa K, Sugino T, Matsumoto S, Chichester P, Whitbeck C, Levin RM. The effect of ovariectomy and estradiol on rabbit bladder smooth muscle contraction and morphology. *J Urol* 2003;170:634–7. <https://doi.org/10.1097/01.ju.0000068723.05004.ca>.
- [33] Cantwell MM, Lacey JV, Schairer C, Schatzkin A, Michaud DS. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. *Int J Cancer* 2006;119:2398–401. <https://doi.org/10.1002/ijc.22175>.
- [34] McGrath M, Michaud DS, Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. *Am J Epidemiol* 2006;163:236–44. <https://doi.org/10.1093/aje/kwj028>.
- [35] Dietrich K, Demidenko E, Schned A, Zens MS, Heaney J, Karagas MR. Parity, early menopause and the incidence of bladder cancer in women: a case–control study and meta-analysis. *Eur J Cancer* 2011;47:592–9. <https://doi.org/10.1016/j.ejca.2010.10.007>.
- [36] Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, et al. Summary of the 8th annual bladder cancer think tank: collaborating to move research forward. *Urol Oncol Semin Orig Investig* 2015;33:53–64. <https://doi.org/10.1016/j.urolonc.2014.06.013>.
- [37] Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. *Cancer Cell* 2014;25:152–65. <https://doi.org/10.1016/j.ccr.2014.01.009>.
- [38] Petrelli F, Coiu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. *Eur Urol* 2014;65:350–7. <https://doi.org/10.1016/j.eururo.2013.06.049>.
- [39] Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, et al. Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer—does pT0 predict better survival than pTa/Tis/T1? *J Urol* 2016;195:886–93. <https://doi.org/10.1016/j.juro.2015.10.133>.
- [40] Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. *Urology* 2014;83:863–8. <https://doi.org/10.1016/j.urolgy.2013.10.060>.
- [41] Lee RK, Abol–Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, et al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. *BJU Int* 2014;113:11–23. <https://doi.org/10.1111/bju.12121>.
- [42] James AC, Lee FC, Izard JP, Harris WP, Cheng HH, Zhao S, et al. Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer. *Clin Genitourin Canc* 2014;12:287–91. <https://doi.org/10.1016/j.clgc.2014.01.005>.
- [43] Zargar-Shoshtari K, Zargar H, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, et al. A multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy. *J Urol* 2016;195:53–9. <https://doi.org/10.1016/j.juro.2015.07.085>.
- [44] Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. *Eur Urol* 2012;61:810–7. <https://doi.org/10.1016/j.eururo.2012.01.017>.
- [45] Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödél CM, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. *Eur Urol* 2014;66:120–37. <https://doi.org/10.1016/j.eururo.2014.02.038>.